PPG

Quick links to important sections

PPG

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of PPG

Property Description
Active ingredient Voglibose
Form Tablet
Pharmacological class Alpha-glucosidase inhibitor (alpha-GI)
Common use Management of high post-meal blood sugar (PPHG)
Origin Synthetic compound

The pharmaceutical preparation known as PPG is an oral anti-diabetic medicine used to help manage high blood sugar levels, particularly those that occur after meals. It is formally classified as an Oral Hypoglycaemic Agent and is intended as an adjunct to diet and exercise for individuals managing their condition, including those with Type 2 Diabetes Mellitus and Impaired Glucose Tolerance (IGT). The original launch of its active component, Voglibose, established its foundation in diabetes therapy globally.


What Type of Medicine is PPG?

PPG belongs to the distinct alpha-glucosidase inhibitor (alpha-GI) pharmacological class of anti-diabetic agents. This drug class is identified under the ATC code A10BF03. This classification confirms that the medicine primarily targets carbohydrate digestion processes. The alpha-GI function involves the competitive inhibition of enzymes located in the small intestine, a core action shared by analogues such as acarbose and miglitol. This pharmacological mechanism is utilized in managing post-meal glucose spikes.


Composition and Identity of PPG

The drug PPG is a single-ingredient product whose sole active ingredient is the synthetic compound Voglibose. Voglibose is chemically characterized as a valiolamine derivative and is presented in the dosage form of a tablet, intended for oral administration. While Voglibose is the International Nonproprietary Name (INN) for the active substance, PPG is a prominent brand. The synthetic compound’s structure is engineered to provide a targeted effect localized to the small intestine.


PPG's General Purpose in Glucose Management

The general purpose of PPG is to moderate blood sugar by slowing of carbohydrate digestion, directly helping to reduce sharp post-meal peaks. This action specifically mitigates the rapid increase in blood sugar known as postprandial hyperglycemia (PPHG). A typical neutral use scenario for this class of medicine is taking it alongside a high-carbohydrate meal to dampen the resulting glucose surge. By inhibiting the enzymes responsible for breaking down complex starches and sugars into absorbable glucose, PPG facilitates a beneficial delayed glucose absorption, contributing to overall glycemic stability critical for the management of Type 2 Diabetes Mellitus.

What side effects are possible with PPG?

Possible Side Effects and Safety Information

The safety profile of PPG (Voglibose) is formalized in official regulatory documents, primarily characterized by adverse reactions related to the gastrointestinal tract, which is a physiological consequence of the medicine's mechanism.


Classification of Officially Documented Adverse Reactions

The most commonly reported adverse reactions are classified under Gastrointestinal Disorders.

System Organ Class Common/Most Commonly Reported Adverse Reactions Serious Adverse Reactions (Rare)
Gastrointestinal Disorders Flatulence, Diarrhea, Abdominal pain, Abdominal distention, Nausea Intestinal Obstruction (Ileus), Pneumatosis Intestinalis
Hepatobiliary Disorders Elevation of Liver Enzymes (GOT, GPT) Fulminant Hepatitis, Serious Liver Dysfunction, Jaundice
Metabolism Disorders Hypoglycemia (in combination therapy) Exacerbation of Hyperammonemia

Key Safety Patterns and Limitations

The most common gastrointestinal effects, such as flatulence and diarrhea, are often more pronounced at the initiation of treatment and are officially documented to gradually decrease with continued use.

A key safety consideration is the risk of hypoglycemia (low blood sugar), which is increased when PPG is used in combination with other anti-diabetic medications, such as insulin or sulfonylureas.

Serious, rare adverse reactions requiring monitoring include liver complications like fulminant hepatitis and intestinal complications such as intestinal obstruction.

Official labeling mandates specific safety limitations: caution is advised for patients with a history of chronic intestinal disease, and the medicine is contraindicated in severe hepatic impairment due to the risk of worsening hyperammonemia, which may lead to a disturbance of consciousness. Close observation is also recommended for elderly patients.

Overdose and Emergency Response

PPG Overdose and When to Seek Help

The official regulatory documentation for PPG (Voglibose) and its pharmacological class details specific expected manifestations and required emergency actions in case of overexposure.


Documented Overdose Presentations

The most commonly documented clinical presentations following an overdose are severe abdominal discomfort and persistent diarrhoea, which are the direct consequences on the gastrointestinal system. Due to the drug’s distinct pharmacological mechanism, Voglibose is formally stated to be unlikely to cause hypoglycemia (low blood sugar) in overdose when it is taken as a standalone therapy.


Serious Risks and Required Emergency Actions

The potential for serious harm necessitates immediate medical care. Regulatory assessments classify the risk from antidiabetic overdoses as one that can lead to major morbidity. Therefore, any suspected overdose requires urgent medical attention and evaluation.

To manage these risks, official documents advise that patients may require stabilization in a facility capable of providing intensive care medicine and may necessitate prolonged hospital stays for comprehensive observation. The standard clinical strategy is largely supportive and focuses on symptomatic treatment to address the acute gastrointestinal distress, as no specific pharmacological antidote is the mandated primary approach for overexposure. This requirement for urgent, high-level care is driven by the potential for major morbidity.

Therapeutic Uses of PPG

What PPG Treats: Main Uses and Benefits

The pharmaceutical preparation PPG (Voglibose) is primarily used across therapeutic domains involving blood sugar regulation. It is relevant in contexts marked by temporary physiological imbalance related to carbohydrate metabolism, providing a focused, supportive intervention for managing chronic conditions and the maintenance of glycemic control.


Key Therapeutic Focus

PPG is commonly used to help with Postprandial Hyperglycemia (PPHG), which is the rapid and significant surge in blood glucose that occurs specifically after eating. The medication may assist with managing symptoms related to systemic imbalance by mitigating these sharp peaks, which contributes to easing the overall symptom load related to glycemic instability. The primary indications include Type 2 Diabetes Mellitus and Impaired Glucose Tolerance (IGT).

“This use may assist with maintaining functional stability and may be relevant in managing the risk associated with progression to Type 2 Diabetes.”

PPG is generally applied in clinical settings that involve acute or unstable symptom patterns where additional symptomatic support is needed. It is commonly used as an adjunct to diet and exercise or incorporated into a combination therapy when existing medication regimens are insufficient to provide adequate glucose control after meals. This generally helps contribute to a greater sense of glycemic stability, which supports general well-being during symptomatic phases and is relevant as part of management strategies for chronic diabetes-related issues.


Quick Fact: Support for Post-Meal Blood Sugar Spikes

Regulatory References

  1. NIH-published review on the use of Voglibose

Eligibility and Restrictions for Use

Who Can and Cannot Use PPG?

The eligibility for PPG (Voglibose) is determined by official regulatory documents, defining populations who are allowed, restricted, or absolutely contraindicated from using the medicine.


Contraindicated Populations

PPG is contraindicated and must not be used by patients with a known hypersensitivity to Voglibose or its excipients. Absolute non-eligibility applies to individuals in acute metabolic instability, such as those with diabetic ketoacidosis or diabetic coma/pre-coma. Use is also prohibited in patients with gastrointestinal obstruction or those who are in a state of acute physical stress, including immediately before or after an operation or with a severe infection.


Age and Physiological Restrictions

The medicine is approved for use in adults with Type 2 Diabetes Mellitus. Safety and effectiveness has not been established in children, making this age group non-eligible for standard use. Geriatric patients may require close observation and may need a specific lower starting dose.


Conditional Use

Use requires caution in patients with a history of laparotomy or ileus, chronic intestinal disease, or those with serious hepatic dysfunction or renal function impairment. For women who are pregnant or breastfeeding, the drug is generally not recommended; administration in pregnancy should occur only if the expected benefit outweighs possible risk.

What should I know about interactions with other medicines?

PPG Interactions with other medicines and products

PPG is a common trade name for the active pharmaceutical ingredient Voglibose, an alpha-glucosidase inhibitor used for managing blood sugar levels, particularly after meals, in type 2 diabetes. Its primary mechanism of action involves slowing down the breakdown of complex carbohydrates in the intestine.


Interaction Scope and Risk

Mechanistic basis of interactions: Primarily a pharmacodynamic interaction related to additive effects on blood glucose levels.

Interacting medicinal products:

Product Class Interaction Type Classification
Other Anti-diabetic Agents (e.g., Insulin, Sulfonylureas, Biguanides) Increased risk of low blood sugar (hypoglycemia) Clinically Significant
Corticosteroids (e.g., Prednisolone) Potential decrease in blood sugar control Use with Caution

Official Interaction Statements

  • Other Diabetes Medications: Concomitant use with other agents that lower blood glucose, such as sulfonylureas, metformin (a biguanide), or insulin, can enhance the glucose-lowering effect and increase the risk of hypoglycemia. Monitoring and potential dose adjustment of the concomitant therapy are required.
  • Medications Affecting Glucose Control: Certain drugs, including corticosteroids, thyroid preparations, and diuretics, can raise blood glucose and may necessitate careful monitoring and potential dosage adjustments of Voglibose to maintain adequate glucose control.
  • Restrictions: There are no absolute do-not-combine (contraindicated) restrictions explicitly tied to drug metabolism for Voglibose in major regulatory labels; however, combinations resulting in excessive lowering of blood glucose must be avoided.

Mechanism of Action

How PPG Works

PPG (Voglibose) operates through two core mechanistic domains localized entirely within the gastrointestinal tract, functioning by modulating carbohydrate metabolism and absorption kinetics.


Competitive Inhibition of Intestinal Enzymes

The drug functions as a reversible, competitive inhibitor of alpha-glucosidase enzymes (specifically disaccharidases like Maltase and Sucrase) found on the brush border of the small intestine. This molecular action directly interferes with the final step of carbohydrate digestion, preventing the rapid breakdown of complex starches and sugars into absorbable glucose. The resulting physiological effect is a delayed and sustained absorption of glucose into the bloodstream. The primary physiological consequence is the attenuation of the postprandial glucose rise; this action limits the magnitude and rate of glucose entry following carbohydrate ingestion.


Secondary Modulation of the Incretin Axis

A secondary but significant action involves the modulation of the enteroendocrine GLP-1 axis. Because the primary inhibition slows digestion, unabsorbed carbohydrates travel to the distal intestine, stimulating specialized L-cells to release the incretin hormone Glucagon-like peptide-1 (GLP-1). This activation results in a systemic slowing of gastric emptying and enhancement of glucose-dependent insulin release.

Dosage and Administration Information

The medicine PPG, which contains the active ingredient Voglibose, is administered orally in the form of tablets. This regimen is designed to align the drug's action with the ingestion of carbohydrates.

Official Dosing and Frequency

The standard starting single dose for adults is 0.2 mg, taken three times a day (TID). This administration must occur immediately before each main meal to ensure the dose is available at the proper time. If initial control is insufficient, the single dose may be increased up to 0.3 mg, which sets the maximum recommended total daily intake at 0.9 mg.

Administration Specifics

For older adults, it is recommended to initiate treatment at a lower dose, such as 0.1 mg, due to the potential for reduced physiological function. Administration-specific rules address the proper handling of missed timing: if a dose is forgotten immediately before a meal, it may be taken during the meal. If a considerable length of time has passed since the meal, the standard protocol is to skip the missed dose and follow the regular schedule; double dosing is strictly prohibited.

The need for continuous administration is subject to re-evaluation. The effectiveness of the drug is assessed by monitoring glucose levels over an initial 2 to 3 month period to determine if ongoing use is necessary.

Recent Clinical Evidence

Evidence for Use in Managing Type 2 Diabetes Mellitus (T2DM)

Voglibose was evaluated in research exploring measurements of glucose levels in the context of T2DM. Research has included short- to intermediate-term Randomized Controlled Trials (RCTs) and Systematic Reviews examining its use in adults with newly diagnosed T2DM or uncontrolled glucose levels while already on other medications. These studies primarily monitored changes in Glycated Hemoglobin ( HbA1 c) and Postprandial Blood Glucose (PPBG).

The data show patterns related to differences in measured PPBG levels in the groups observed, and research highlights changes measured during the study period for HbA1 c when the agent was applied in combination with other existing treatments. The data remains limited on the specific contribution of Voglibose alone, as much of the high-quality research was evaluated in combination therapy.


Evidence for Preventing Progression to Type 2 Diabetes

Voglibose was evaluated in major, placebo-controlled clinical trials that research examined for their potential to impact the progression of diabetes. This research examined the impact on the incidence of progression to overt Type 2 Diabetes in high-risk individuals diagnosed with Impaired Glucose Tolerance (IGT).

Findings describe patterns observed in the studies where the rate of progression to T2DM was different between the group receiving the agent and the placebo group. The study results reflect the specific conditions under which they were conducted, and the research population, comprised mainly of Japanese adults with IGT, may limit the wide applicability of these findings.


Understanding Research Gaps and Areas of Uncertainty

For many core trials, follow-up durations were limited. Consequently, limited information is available regarding the agent's impact on critical endpoints such as major cardiovascular events (like heart attack or stroke) or overall mortality. The data for certain groups remain insufficient, including populations such as children, adolescents, and pregnant individuals. Furthermore, the findings varied across studies focusing on secondary metabolic markers, such as lipids, and long-term effects are not fully established. Findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Alpha-Glucosidase Inhibitors - NCBI Bookshelf (StatPearls Review)
  2. ATC/DDD Index 2025 - A10BF03 (Voglibose)

Frequently Asked Questions (FAQ)

Common questions about PPG (FAQ)


Q: Is flatulence or gas a side effect that eventually goes away while taking PPG?

Regulatory documents indicate that common gastrointestinal side effects, such as flatulence and diarrhea, are often more noticeable when a person first starts taking the medication. Official information states that these effects generally tend to decrease gradually with continued use as the body adjusts to the drug’s mechanism of action.

Q: What is the risk of hypoglycemia (low blood sugar) with PPG compared to other diabetes drugs?

When used alone (monotherapy), PPG carries a low risk of causing hypoglycemia, according to official product information. However, the risk of low blood sugar is significantly increased if PPG is taken in combination with other anti-diabetic agents, such as insulin or sulfonylureas. Glucose levels are typically monitored closely when combining these treatments.

Q: Does PPG affect my liver or kidney health, and what signs should I watch for?

PPG use has been associated with elevations in liver enzymes, and rare cases of serious liver dysfunction have been reported. For this reason, regulatory information states the medicine is contraindicated in severe hepatic impairment, and caution is required for those with severe kidney impairment.

Q: What specific type of blood sugar test is PPG designed to help control (e.g., A1C, fasting, or post-meal)?

The primary action of PPG is to delay glucose absorption into the bloodstream. This action is specifically intended to attenuate, or lessen, the rise in postprandial glucose (the sugar spike that occurs after a meal). Effectiveness is assessed by monitoring both post-meal sugar and the longer-term average, HbA1 c.

Q: What are the signs of an allergic reaction to PPG that require immediate medical attention?

PPG is contraindicated for individuals with known hypersensitivity (allergy) to the drug or its components. Any sign of a serious allergic reaction, such as a severe rash, swelling, or difficulty breathing, requires immediate medical observation.

Q: If I am taking blood thinners, is it safe to also take PPG?

Regulatory summaries generally advise caution when combining PPG with blood thinners (anticoagulants), such as warfarin. It is generally advised that a healthcare provider be informed of all medicines being taken, as monitoring may be necessary to manage any potential interactions.

Q: Can I take pain relievers, like ibuprofen, while I am on PPG?

Official drug interaction lists do not explicitly prohibit the use of common pain relievers like ibuprofen with PPG. However, caution and monitoring are advised when diabetic patients use certain non-steroidal anti-inflammatory drugs (NSAIDs), especially if the NSAID use is long-term or affects kidney function.

Q: What is the difference between PPG 0.2mg and PPG 0.3mg tablets in terms of effect?

Official regulatory dosing information mentions different tablet strengths. The maximum approved dose is available if initial glucose control with a lower dose is determined to be insufficient, suggesting a stronger effect is sought in those cases.

Q: What kinds of food or drinks should be avoided while taking PPG?

PPG is intended to be used alongside a prescribed dietary therapy that must be strictly followed. Additionally, official instructions clarify that table sugar (sucrose) is not the appropriate treatment for low blood sugar while taking this medicine, as it will not raise glucose levels quickly.

Q: Are there any specific supplements or herbal remedies that might interact with PPG?

Official patient guidance strongly advises informing a healthcare provider about all products being taken, including over-the-counter medicines, herbal products, and dietary supplements. This is because some supplements may interact with PPG, either enhancing or diminishing its intended effect on blood sugar levels.

Q: Why is table sugar not recommended to treat low blood sugar if a person is on PPG?

PPG works by inhibiting the enzyme that breaks down complex sugars, including table sugar (sucrose), into absorbable glucose. Because this breakdown is slowed, using table sugar to treat low blood sugar (hypoglycemia) will not raise glucose levels quickly enough. Pure glucose (dextrose) must be used instead for rapid treatment.

Q: Is it possible to take PPG for a while and then stop if my blood sugar improves?

Official drug documents state that the need for continuous use is subject to re-evaluation by a physician. A reassessment of the drug’s effectiveness is typically recommended after an initial monitoring period of about two to three months to determine if ongoing use is necessary for control.

Q: Are there any long-term effects or risks associated with taking PPG for many years?

Regulatory data acknowledges that many of the core clinical trials had limited follow-up durations. Consequently, official documents note that information on long-term effects, particularly regarding major cardiovascular events or overall mortality, is not fully established.

Q: Can PPG be used in people who have pre-diabetes or just mild insulin resistance?

Yes, official indications state that PPG is approved as an adjunct to diet and exercise for individuals managing Type 2 Diabetes Mellitus and those with Impaired Glucose Tolerance (IGT). IGT is a condition often referred to as pre-diabetes.

Q: Can I drive or operate machinery if I experience dizziness after taking PPG?

Official patient leaflets caution that the medicine may cause hypoglycemia (low blood sugar), which can lead to side effects such as dizziness. Patients are therefore advised to exercise care when performing potentially dangerous tasks, such as driving a car or operating machinery.

Q: Can I take a combination pill with PPG and other diabetes drugs?

PPG (Voglibose) is approved as a single-ingredient product. However, the active ingredient Voglibose is also found in other branded products that are manufactured as a combination pill with a second anti-diabetic agent.

Q: Does the time of day matter when taking PPG if I have an unusual eating schedule?

Timing is important because PPG must be taken immediately before each main meal to align its action with carbohydrate ingestion. Official guidance also specifies that if a dose is forgotten immediately before a meal, it may still be taken during the meal itself.

Q: Is it okay to take PPG if I occasionally consume alcohol?

Regulatory safety advice indicates that consuming alcohol while taking this medication is considered unsafe. This is because alcohol consumption may increase the risk of hypoglycemia (low blood sugar levels).

Q: Does PPG interact with common medications for high blood pressure or high cholesterol?

Regulatory documents state that certain medications, including some diuretics used for high blood pressure, can interfere with blood glucose control by raising sugar levels. This requires careful monitoring and potential dosage adjustments of PPG.

Q: Does PPG's effect on carbohydrate breakdown apply to all types of carbohydrates?

The drug works by inhibiting the alpha-glucosidase enzymes, which are responsible for breaking down complex carbohydrates (starches) and disaccharides (certain sugars) into absorbable glucose. This action focuses primarily on these specific types of carbohydrates.

Q: What patient groups are specifically excluded from using PPG?

Absolute contraindications for PPG include known hypersensitivity to the drug, active diabetic ketoacidosis, and conditions involving gastrointestinal obstruction. Additionally, official labeling states that the medication is not established as safe or effective for use in children.

Q: What kind of diet is best to follow when taking PPG?

PPG is intended to be used as an adjunct to diet and exercise therapy. Official patient instructions emphasize the importance of strictly following the prescribed dietary therapy, as the medicine's mechanism is specifically dependent on the patient's carbohydrate intake.

Q: Is it normal to feel bloated or full after meals when taking PPG?

Yes, official safety information lists abdominal distention, which is the medical term for bloating or a feeling of fullness, as a common adverse reaction. This is often linked to the drug's mechanism of slowing down carbohydrate digestion in the intestine.

Q: How often should blood sugar levels be monitored when first starting on PPG?

Regulatory guidance suggests that a physician should evaluate the effectiveness of the drug by monitoring glucose levels over an initial period of about two to three months. This implies that close observation and monitoring are needed, especially when the treatment is first initiated or the dose is adjusted.

Q: Does PPG work better when combined with exercise, and why?

Official indications for PPG confirm that it is intended for use as an adjunct to diet and exercise. The medication should be used as part of a comprehensive lifestyle management plan, meaning that exercise and diet remain essential components of therapy.

Q: Are there any common over-the-counter cold and flu medications that should be avoided with PPG?

Official guidance advises informing a healthcare provider about all medicinal products being taken, including over-the-counter cold and flu preparations. This is because some non-prescription products may contain ingredients that can affect blood sugar levels or interact with PPG's effects.

Q: Is there any research about PPG's effectiveness in children or adolescents with diabetes?

According to official regulatory restrictions, the safety and effectiveness of PPG have not been established in children or adolescents. Therefore, the medication is typically not eligible for use in this age group.

How should PPG be stored and disposed of?

How to Store and Dispose of PPG (Voglibose Tablets)

Official regulatory guidelines strictly define the conditions necessary for storing and discarding PPG to ensure stability and safety.


Mandatory Storage Requirements

Element Requirement
Temperature Store at a controlled room temperature.
Protection Keep the tablets protected from moisture and away from direct sunlight.
Container Keep the medicine in the original container.

Handling and Disposal

It is mandatory to keep this medicine out of the sight and reach of children.

Do not use the tablets after the expiry date shown on the package. To dispose of unused or expired PPG, patients must ask a pharmacist how to throw away the medicine. Regulatory rules prohibit disposal of this medicine via wastewater or household rubbish.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of PPG found in:

A-Z Index: